For example, while we have exemplified the technology here using a BiTE that recognises a carcinoma‐associated antigen (EpCAM), it is also possible to use the BiTE approach to target cytotoxicity to tumour‐associated fibroblasts or other stromal cells. This evidence concerns the gene EPCAM and neoplasm.